BioCentury
ARTICLE | Clinical News

Novartis' Kisqali combo meets PFS endpoint in Phase III for breast cancer in postmenopausal women

July 6, 2018 4:44 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the Phase III MONALEESA-3 trial to treat breast cancer showing that Kisqali ribociclib in combination with Faslodex fulvestrant met the primary endpoint of improving median progression-free survival (PFS) vs. Faslodex alone (20.5 vs. 12.8 months, p=0.00000041). The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago and published in the Journal of Clinical Oncology.

The double-blind, international trial enrolled 726 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who have received no prior or only one line of prior endocrine therapy for advanced disease...